Brind.

Morgan Stanley initiated coverage on July 11, 2025, with a Buy rating, noting that Voxzogo is BioMarin's therapy for achondroplasia and that TransCon CNP could be a competitor.

1 report, 1 independent Updated Jul 11

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Morgan Stanley BioMarin Pharmaceutical Ascendis Pharma (Denmark)

Keep exploring

The entities involved

Morgan Stanley
U.S. investment bank
- Financial firms including Morgan Stanley, Truist Financial, Jefferies Financial Group, and CIBC issued rating and price objective updates for Clearway Energy.Mon 17:33
- Goldman Sachs, Morgan Stanley, JPMorgan Chase, and Bank of America are competing in the global investment banking sector.Mon 17:24
BioMarin Pharmaceutical
American company
- Investors are comparing the financial performance metrics of BioMarin Pharmaceutical and Metagenomi.Sun 20:41
Ascendis Pharma (Denmark)
company in Copenhagen, Denmark

Nothing else this week.

Coverage

Newest first; wire copies grouped

Jul 11Insider MonkeyMorgan Stanley Sees Rebound Potential in BioMarin (BMRN), Highlights Underappreciated Voxzogo Upside BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the 11 best debt-free stocks to invest in rig